The most significant published evidence on retatrutide to date comes from a Phase 2 randomised controlled trial, the results of which were published in the New England Journal of Medicine in June 2023 (Jastreboff et al.)
For the weight management indication (Zepbound), suicidal ideation and behavior have been reported, and patients should be monitored for new or worsening depression, suicidal thoughts, or unusual behavior changes
Many healthcare professionals and patient safety advocates argue that the modest additional cost of 503B-sourced medications is a worthwhile investment in safety, particularly for injectable products
Beaudet also is professor of molecular and cellular biology and of pediatrics at Baylor
Such studies would need to consider the heterogeneity of IBS, potentially focusing on subgroups of patients more likely to benefit from Semaglutides specific mechanisms of action, such as those with IBS-C or mixed-type IBS